Skip to main content

Advertisement

Table 1 Characteristics of the participants at baseline

From: Adherence to inhaled therapy and its impact on chronic obstructive pulmonary disease (COPD)

  All Female Male p-value
n (%) 357 122 (34.2) 235 (65.8)  
Age in year, mean (SD) 66.5 (10.6) 66.1 (11.1) 66.7 (10.0) 0.580
FEV1%pred., mean (SD) 55.0 (18.5) 58.0 (19.4) 53.4 (17.9) 0.067
Smoking status, n (%)
 Current smoker 126 (35.3) 43 (35.3) 83 (35.3) 0.982
 Former smoker 205 (57.4) 67 (54.9) 138 (58.7) 0.471
 Never smoker 14 (3.9) 8 (6.5) 6 (2.6) 0.065
 No information 12 (3.4) 4 (3.3) 8 (3.4)  
Inhaled Therapy, n (%)
 LAMA only 10 (2.8) 3 (2.5) 7 (3.0) 0.777
 LABA only 3 (0.8) 2 (1.6) 1 (0.4) 0.233
 LABA + ICS 64 (17.9) 34 (27.9) 30 (12.8) <  0.001
 LAMA + LABA + ICS 275 (77.0) 80 (65.6) 195 (83.0) <  0.001
 LABA + LAMA 5 (1.4) 3 (2.5) 2 (0.9) 0.952
LTOT, n (%) 60 (17.0) 26 (21.5) 34 (14.7) 0.101
  1. LAMA – long-acting muscarinic antagonist; LABA – long-acting beta-adrenoceptor agonist; ICS – inhaled corticosteroid; LTOT – long-term oxygen therapy